FDA Hits Baxter With Two Warning Letters In Four Weeks
This article was originally published in The Gray Sheet
Executive Summary
The warning letters cite quality system regulation violations related to the firm’s infusion pumps, including inadequate corrective and preventive actions related to complaints of over-infusion and device bladder ruptures.